NCT03711578View on ClinicalTrials.gov

Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 25, 2018

Primary Completion Date

June 16, 2020

Study Completion Date

October 16, 2020

Conditions
Non Hodgkin Lymphoma
Interventions
DRUG

Tenalisib,

BID, Orally

Trial Locations (12)

2148

Blacktown Hospital, Blacktown Cancer and Haematology Center, Blacktown

4120

Brisbane Clinic for Lymphoma, Myeloma and Leukaemia,, Greenslopes

4224

John Flynn Private Hospital,, Tugun

5000

Royal Adelaide Hospital, Adelaide

33401

Florida cancer specialists & Research Institute, Florida City

33705

Florida Cancer Specialists/North, St. Petersburg

33908

Florida Cancer Specialist/ South, Fort Myers

35805

Clearview Cancer Institute, Huntsville

37203

Tennessee Oncology, Nashville

37404

Tennessee Oncology, Chattanooga

64132

HCA Midwest Health Kansas City, Kansas City

80218

Colorado Blood Cancer Institute, Denver

All Listed Sponsors
lead

Rhizen Pharmaceuticals SA

INDUSTRY

NCT03711578 - Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL) | Biotech Hunter | Biotech Hunter